Investigation of Transcript Variant 6 of TPD52L2 as a Prognostic and Predictive Biomarker in Basal-Like MDA-MB-231 and MDA-MB-453 Cell Lines for Breast Cancer

Figure 6

Expression of V6 of tpd52l2 in patients with different pathological characteristics and its impact on survival and therapy response. (a) Comparative analysis of transcript expression of V6 in breast cancer patients with pathological_M0 status and pathological_M1 status. (b) Comparative analysis of transcript expression of V6 in breast cancer patients with pathological_N0 status and higher status (N1, N2, and N3). (c) Comparative analysis of transcript expression of V6 in breast cancer patients or BLBC patients with lower pathological T stage (T1 and T2) and higher pathological T stage (T3 and T4). (d) Comparative analysis of transcript expression of V6 in breast cancer patients or BLBC patients with different pathological stages (stages I, II, III, and IV). (e) Kaplan–Meier curves indicating the OS, DFS, and PFI of breast cancer patients in the BRCA cohort. (f) Kaplan–Meier curves indicating the OS of breast cancer patients who received radiation therapy or targeted therapy in the BRCA cohort (Kaplan–Meier analysis with log-rank test for survival analysis, Mann–Whitney test for expression analysis, ).

(a)

(b)

(c)

(d)

(e)

(f)